AU2018275122A1 - Dosing schedule for tesetaxel and capecitabine - Google Patents

Dosing schedule for tesetaxel and capecitabine Download PDF

Info

Publication number
AU2018275122A1
AU2018275122A1 AU2018275122A AU2018275122A AU2018275122A1 AU 2018275122 A1 AU2018275122 A1 AU 2018275122A1 AU 2018275122 A AU2018275122 A AU 2018275122A AU 2018275122 A AU2018275122 A AU 2018275122A AU 2018275122 A1 AU2018275122 A1 AU 2018275122A1
Authority
AU
Australia
Prior art keywords
capecitabine
day
administering
day cycle
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018275122A
Other languages
English (en)
Inventor
Stew KROLL
John G. Lemkey
Steven Pfeiffer
Kevin Tang
Jeff VACIRCA
Thomas Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Odonate Inc
Original Assignee
Odonate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odonate Therapeutics Inc filed Critical Odonate Therapeutics Inc
Publication of AU2018275122A1 publication Critical patent/AU2018275122A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018275122A 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine Abandoned AU2018275122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514483P 2017-06-02 2017-06-02
US62/514,483 2017-06-02
PCT/US2018/035653 WO2018223029A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Publications (1)

Publication Number Publication Date
AU2018275122A1 true AU2018275122A1 (en) 2019-12-19

Family

ID=64455637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018275122A Abandoned AU2018275122A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Country Status (14)

Country Link
US (1) US20200179427A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630091A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020522568A (cg-RX-API-DMAC7.html)
KR (1) KR20200014880A (cg-RX-API-DMAC7.html)
CN (1) CN111032035A (cg-RX-API-DMAC7.html)
AU (1) AU2018275122A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019025164A2 (cg-RX-API-DMAC7.html)
CA (1) CA3065783A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992852A1 (cg-RX-API-DMAC7.html)
IL (1) IL270973A (cg-RX-API-DMAC7.html)
MA (1) MA50039A (cg-RX-API-DMAC7.html)
MX (1) MX2019014489A (cg-RX-API-DMAC7.html)
TW (1) TW201902473A (cg-RX-API-DMAC7.html)
WO (1) WO2018223029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019359755A1 (en) * 2018-10-17 2021-05-20 Odonate Therapeutics, Inc. Methods of treating CNS tumors with tesetaxel
TW202112364A (zh) * 2019-08-16 2021-04-01 美商蜻蛉治療股份有限公司 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法
WO2022177835A1 (en) * 2021-02-16 2022-08-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201701880A (zh) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法

Also Published As

Publication number Publication date
MA50039A (fr) 2020-07-08
JP2020522568A (ja) 2020-07-30
KR20200014880A (ko) 2020-02-11
CA3065783A1 (en) 2018-12-06
MX2019014489A (es) 2020-08-17
EA201992852A1 (ru) 2020-03-27
BR112019025164A2 (pt) 2020-06-16
WO2018223029A1 (en) 2018-12-06
US20200179427A1 (en) 2020-06-11
CN111032035A (zh) 2020-04-17
TW201902473A (zh) 2019-01-16
EP3630091A1 (en) 2020-04-08
EP3630091A4 (en) 2021-03-10
IL270973A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
ES2228932T3 (es) Procedimiento de tratamiento del carcinoma positivo de estrogenos.
AU2013205648B2 (en) Combination treatment
ES2626134T3 (es) Composiciones de bepotastina
US7834056B2 (en) Pharmaceutical composition for gout
EA030335B1 (ru) Применение амисульприда в качестве противорвотного средства
WO2018223029A1 (en) Dosing schedule for tesetaxel and capecitabine
WO2019067860A1 (en) COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH
WO2020150146A1 (en) Compositions and methods for treating cardiac injury
WO2021034335A1 (en) Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers
ES2984281T3 (es) Composiciones que comprenden un antagonista de la aldosterona para su uso en el tratamiento de ojos secos
WO2022197293A1 (en) Methods of administering tesetaxel to patients with hepatic impairment
WO2024050145A1 (en) Thiostrepton dosing regimens
HK40029016A (en) Dosing schedule for tesetaxel and capecitabine
WO2022197290A1 (en) Methods of administering tesetaxel with cyp3a4 inhibitors
US20210386720A1 (en) Methods of treating cns tumors with tesetaxel
EP2485729A1 (en) Treatment with cholinergic agonists
TW202114717A (zh) 含有對硼苯基丙胺酸之注射液劑
WO2026015820A1 (en) Methods of treating vexas
KR20250044649A (ko) X-ald 치료를 위한 갑상선 베타-작용제 투여 요법
WO2022265984A1 (en) Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
HK40123938A (en) Thyroid beta-agonist dosing regimens for the treatment of x-ald
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
WO2009056256A1 (en) Use of megestrol acetate having improved solubility for the treatment of cancer cachexia
EA028400B1 (ru) Способ профилактики и лечения ожирения и избыточного веса и связанных с ними нарушений

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period